Damae Medical has secured €15 million in Series B funding to advance its deepLive™ technology, revolutionizing dermatological diagnostics through 3D digital biopsies and AI integration.

Information on the Target

Damae Medical is a pioneering French company focused on advancing dermatological care through innovative imaging technology and artificial intelligence (AI). The company has recently raised €15 million in Series B funding to enhance its flagship product, the deepLive™, which is designed to transform the diagnostics process for skin cancers. This device allows dermatologists to perform non-invasive cellular imaging, providing real-time diagnostic insight during patient consultations, thus reducing the reliance on traditional biopsies that can lead to delays in treatment.

The deepLive™ technology is rooted in a decade of research and development, led by Professor Arnaud Dubois at the Charles Fabry Laboratory in conjunction with the CNRS and Université Paris-Saclay. It uses LC-OCT technology for 3D digital biopsies, enabling practitioners to visualize skin cells in real-time. This not only aids in immediate diagnostic orientation but also helps surgeons assess lesion depths prior to excision, thereby minimizing the risk of incomplete removal and safeguarding surrounding healthy tissue.

Industry Overview in France

The dermatology sector in France is undergoing significant transformation, driven by advancements in technology and increasing demand for effective skin cancer diagnostics. Skin cancer is one of the most prevalent c